Movers and SHAKERS
Onconova Therapeutics Inc. (ONTX)
Recent MDS data and what it means for Onconova
Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
New data in MDS. Onconova presented data at the American Society of Hematology (ASH) annual meeting in December. The data update included genomic profiling from INSPIRE study patients, who suffer from higher risk myelodysplastic syndrome (HR-MDS). We don't expect any value generating data until topline readout from INSPIRE study in 2020. In this report, we have highlighted recent data readouts in MDS landscape.
What's new in MDS and what it means for rigosertib. Forty Seven (FTSV, Not covered)'s magrolimab and Abbvie (ABBV, Not covered)'s venetoclax made the most impact in HR-MDS field. Onconova's rigosertib has shown similar ORR to magrolimab (92%), but superior ORR to venetoclax (90% versus 70%). Magrolimab showed the highest CR rates with...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.